The role of neoadjuvant therapy for locally advanced breast cancer is undisputed and is due to the treatment algorithm an appropriate object of clinical studies. Even though the patient of luminal hormone treatment benefit, are not information about the benefits of chemotherapy. At the luminal tumors B is proved a unique profit from treatment antracykliny and taxan, especially at the luminal HER pozitive type. The introduction of Intrinsic subtype into the treatment of advanced tumor subtype of breast cancer has a unique output. For subtypes of luminal A axillae nodes pozitive was profit from chemotherapy proved, in the case of luminal B is profit unique, the most benefits for a group of Luminal HER positive tumors, where in the case of neoadjuvance wait until 50% of pathological complete remission (pCR) and overall survival is better than luminal B without the positivity of the HER. The best experiences are in neoadjuvant with the antracyklins and taxans , in the case of luminal A does not benefit from antracyklins unique, and you can choose nonantracyklin mode. At the luminal HER group (Luminal B HER+) shows a better answer a combination of inhibitors of the HER receptor (pertuzumab), however the results we need to definitive some time to wait. At the luminal tumors HER 2 neu positive Luminal A pCR does not correlate with the overall survival.